Trialkyne linking agents and methods of use

US12065458B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12065458-B2
Application numberUS-201916970130-A
CountryUS
Kind codeB2
Filing dateFeb 15, 2019
Priority dateFeb 17, 2018
Publication dateAug 20, 2024
Grant dateAug 20, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound of Formula III, or a pharmaceutically acceptable salt thereof, wherein, L 1 , L 2 , and L 3 are each linkers of the formula: L 4 is selected from the group consisting of: wherein indicates the point of attachment; R 4 is H or optionally substituted alkyl; X is O or S; and RNA comprises or consists of an RNAi agent. 2. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein X is O. 3. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein X is S. 4. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein L 1 , L 2 , and L 3 are each 5. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein L 1 , L 2 , and L 3 are each 6. The compound or pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is selected from the group consisting of: Compound No. Structure 1-O-III 1-S-III 2-O-III 2-S-III 3-O-III 3-S-III 4-O-III 4-S-III 5-O-III 5-S-III 6-O-III 6-S-III 7-O-III 7-S-III 8-O-III 8-S-III 9-O-III 9-S-III 10-O-III 10-S-III 11-O-III

Assignees

Inventors

Classifications

  • Conjugate · CPC title

  • interfering nucleic acids [NA] · CPC title

  • Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

  • containing three or more hetero rings · CPC title

  • having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12065458B2 cover?
Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interfere…
Who is the assignee on this patent?
Arrowhead Pharmaceuticals Inc
What technology area does this patent fall under?
Primary CPC classification A61K47/545. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).